CB1 receptors on brain cells versus star-shaped support cells control endocannabinoid 2-AG in opposite directions
In mice, CB1 receptors on glutamate neurons and astrocytes exerted opposite control over the turnover rate of the endocannabinoid 2-AG in the frontal cortex.
Quick Facts
What This Study Found
Researchers used genetically modified mice lacking CB1 receptors on specific cell types to understand how different cells regulate the endocannabinoid 2-AG. When CB1 receptors were absent from glutamate neurons, 2-AG turnover in the frontal cortex decreased. When CB1 receptors were absent from astrocytes (support cells), 2-AG turnover increased.
Despite these opposite effects on 2-AG production and degradation rates, baseline 2-AG levels remained constant across all genotypes. This was because the body compensated: changes in synthesis rates were matched by proportional changes in degradation rates.
This cell-type-specific regulation was primarily observed in the frontal cortex, with some effects in the hippocampus. The striatum showed minimal genotype effects.
Key Numbers
Three genotypes of conditional knockout mice tested. Three brain regions examined. 2-AG accumulation rates decreased in frontal cortex of glutamate neuron knockouts and increased in frontal cortex and hippocampus of astrocyte knockouts.
How They Did This
Controlled animal study using three lines of conditional knockout mice, each lacking CB1 receptors from one cell type: forebrain GABAergic neurons, cortical glutamatergic neurons, or astrocytes. Mice were treated with JZL195, a dual enzyme inhibitor, and endocannabinoid levels were measured in frontal cortex, hippocampus, and striatum.
Why This Research Matters
Understanding that different cell types regulate endocannabinoids in opposite directions has implications for developing targeted cannabis-based therapies. It explains why simply measuring endocannabinoid levels at a single time point may miss important dynamic changes.
The Bigger Picture
The endocannabinoid system is more complex than a simple on/off switch. Different cell types in different brain regions fine-tune cannabinoid signaling in distinct, sometimes opposing ways. This complexity is why cannabis can produce such varied effects across brain functions.
What This Study Doesn't Tell Us
Animal study results may not directly translate to humans. The conditional knockout approach completely removes receptors from a cell type rather than modulating them, which is more extreme than natural variation. JZL195 blocks both FAAH and MAGL simultaneously.
Questions This Raises
- ?Could targeting CB1 receptors on specific cell types produce more precise therapeutic effects?
- ?Does this cell-type-specific regulation change with chronic cannabis use?
- ?Are similar patterns present in human brain tissue?
Trust & Context
- Key Stat:
- Opposite 2-AG regulation by neurons vs. astrocytes
- Evidence Grade:
- Controlled animal study with genetic precision but limited human translatability.
- Study Age:
- Published in 2015. Basic science research on cell-type-specific endocannabinoid regulation continues.
- Original Title:
- Opposite control of frontocortical 2-arachidonoylglycerol turnover rate by cannabinoid type-1 receptors located on glutamatergic neurons and on astrocytes.
- Published In:
- Journal of neurochemistry, 133(1), 26-37 (2015)
- Authors:
- Belluomo, Ilaria, Matias, Isabelle(3), Pernègre, Camille, Marsicano, Giovanni, Chaouloff, Francis
- Database ID:
- RTHC-00918
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is 2-AG?
2-arachidonoylglycerol (2-AG) is one of the two main endocannabinoids, naturally produced signaling molecules that activate the same receptors as THC in cannabis. It plays roles in mood, pain, appetite, and brain function.
Why does this study matter?
It shows that the endocannabinoid system is not uniformly regulated. Different cell types control it in opposite directions, which helps explain the complexity of cannabis effects and could guide more targeted drug development.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00918APA
Belluomo, Ilaria; Matias, Isabelle; Pernègre, Camille; Marsicano, Giovanni; Chaouloff, Francis. (2015). Opposite control of frontocortical 2-arachidonoylglycerol turnover rate by cannabinoid type-1 receptors located on glutamatergic neurons and on astrocytes.. Journal of neurochemistry, 133(1), 26-37. https://doi.org/10.1111/jnc.13044
MLA
Belluomo, Ilaria, et al. "Opposite control of frontocortical 2-arachidonoylglycerol turnover rate by cannabinoid type-1 receptors located on glutamatergic neurons and on astrocytes.." Journal of neurochemistry, 2015. https://doi.org/10.1111/jnc.13044
RethinkTHC
RethinkTHC Research Database. "Opposite control of frontocortical 2-arachidonoylglycerol tu..." RTHC-00918. Retrieved from https://rethinkthc.com/research/belluomo-2015-opposite-control-of-frontocortical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.